Skip to content

Study · Not a test of the peptide alone · 2023

7 results

Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.

Roof E, Deal CL, McCandless SE, Cowan RL, Miller JL, Hamilton JK, Roeder ER, McCormack SE, Roshan Lal TR, Abdul-Latif HD, Haqq AM, Obrynba KS and 25 more

Show all authors

Torchen LC, Vidmar AP, Viskochil DH, Chanoine JP, Lam CKL, Pierce MJ, Williams LL, Bird LM, Butler MG, Jensen DE, Myers SE, Oatman OJ, Baskaran C, Chalmers LJ, Fu C, Alos N, McLean SD, Shah A, Whitman BY, Blumenstein BA, Leonard SF, Ernest JP, Cormier JW, Cotter SP, Ryman DC

The Journal of clinical endocrinology and metabolism1 Jun 2023Cited by 39 (Europe PMC)

PMID36633570 (opens in a new tab)PMCIDPMC10271225 (opens in a new tab)DOI10.1210/clinem/dgad015 (opens in a new tab)PepBankPUB-36633570
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 01HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome

    In participants with Prader-Willi syndrome, 9.6 mg intranasal carbetocin gave a numeric but not statistically significant improvement in HQ-CT hyperphagia versus placebo.

    In plain wordsIn young people with Prader-Willi syndrome, the oxytocin analog carbetocin at the higher dose did not significantly reduce hyperphagia compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeHyperphagia (HQ-CT), 9.6 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    The primary endpoints showed numeric improvements in both HQ-CT and CY-BOCS which were not statistically significant
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 02HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome

    In participants with Prader-Willi syndrome, 9.6 mg intranasal carbetocin gave a numeric but not statistically significant improvement in CY-BOCS versus placebo.

    In plain wordsIn young people with Prader-Willi syndrome, the oxytocin analog carbetocin at the higher dose did not significantly reduce obsessive-compulsive symptoms compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeObsessive-compulsive symptoms (CY-BOCS), 9.6 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    The primary endpoints showed numeric improvements in both HQ-CT and CY-BOCS which were not statistically significant
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 03HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome

    In participants with Prader-Willi syndrome, 3.2 mg intranasal carbetocin gave nominally significant improvement in HQ-CT versus placebo.

    In plain wordsIn young people with Prader-Willi syndrome, the lower dose of the oxytocin analog carbetocin nominally reduced hyperphagia compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseHyperphagia (HQ-CT), 3.2 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    the 3.2-mg arm showed nominally significant improvements in HQ-CT
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  4. 04HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome

    In participants with Prader-Willi syndrome, 3.2 mg intranasal carbetocin gave nominally significant improvement in PADQ versus placebo.

    In plain wordsIn young people with Prader-Willi syndrome, the lower dose of the oxytocin analog carbetocin nominally reduced anxiousness and distress compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseAnxiousness and distress behaviors (PADQ), 3.2 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    the 3.2-mg arm showed nominally significant improvements in HQ-CT, PADQ, and CGI-C scores vs placebo.
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  5. 05HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome

    In participants with Prader-Willi syndrome, 3.2 mg intranasal carbetocin gave nominally significant improvement in CGI-C scores versus placebo.

    In plain wordsIn young people with Prader-Willi syndrome, the lower dose of the oxytocin analog carbetocin nominally improved the clinician global rating compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedClinical global impression of change (CGI-C), 3.2 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    the 3.2-mg arm showed nominally significant improvements in HQ-CT, PADQ, and CGI-C scores vs placebo.
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  6. 06HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome

    In participants with Prader-Willi syndrome, improvements with intranasal carbetocin were sustained in the 56-week long-term follow-up period.

    In plain wordsIn young people with Prader-Willi syndrome, improvements seen with the oxytocin analog carbetocin were sustained during long-term follow-up.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedLong-term maintenance of improvements
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Improvements were sustained in the long-term follow-up period.
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  7. 07HumanNot a test of Oxytocin aloneRandomized controlled trialSafety outcome

    In participants with Prader-Willi syndrome, the most common adverse event with intranasal carbetocin during the placebo-controlled period was mild to moderate flushing.

    In plain wordsIn young people with Prader-Willi syndrome, the most common side effect of the oxytocin analog carbetocin was mild to moderate flushing.

    Peptide
    Oxytocin
    Outcome
    Not applicableMost common adverse event (flushing)
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    The most common adverse event during the PCP was mild to moderate flushing.
    1 context sentence
    Summary · context
    Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.